Top in GI: Dual biologic therapy in IBD; hyperbaric oxygen therapy in fistulizing Crohn’s

Last week, Healio provided coverage of the Crohn’s and Colitis Congress.

During one of the presentations, researchers reported that early dual biologic therapy may be safe and effective in patients with inflammatory bowel disease. It was the top story in gastroenterology last week.

Another top story was about a presentation that examined hyperbaric oxygen therapy as a treatment for fistulizing Crohn’s disease. Researchers found that it was associated with a clinical response rate of 87%, “suggesting that hyperbaric oxygen therapy may be an effective treatment option for fistulizing disease,” Amr Dokmak, MD, a hospitalist at Catholic Medical Center in Manchester, New Hampshire, told Healio.

Read these and more top stories in gastroenterology below:

‘Why not combine them?’: Early dual biologic therapy may overcome limits in severe IBD

Early data suggest combination therapy with biologics or advanced small-molecules may be safe and effective in patients with inflammatory bowel disease, according to a presenter at the Crohn’s and Colitis Congress. Read more.

Hyperbaric oxygen therapy ‘safe and potentially effective’ for fistulizing Crohn’s

Hyperbaric oxygen therapy yielded a clinical response rate of 87% among patients with fistulizing Crohn’s disease with few adverse events, according to systematic review data. Read more.

Dietitians ‘a valuable resource’ in multidisciplinary IBD care team

A varied and well-balanced diet plays “a significant role” in the management of patients with inflammatory bowel disease and can be guided with support from a dietitian, a presenter reported. Read more.

‘Sociocultural influences’ must factor into nutritional strategies for patients with IBD

Health care providers should apply cultural competency, sensitivity and humility when making dietary recommendations for patients with inflammatory bowel disease, noted a presenter. Read more.

VIDEO: Evidence suggests it is safe to use preoperative biologics in IBD patients

In a Healio video exclusive, Stefan D. Holubar, MD, MS, discusses the decades-long controversy surrounding preoperative use of biologics and risk for postoperative complications in patients with inflammatory bowel disease. Watch video.